Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 3/20 | 0.60 |
| ▸ | CTSL | P07711 | 2/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | CTSS | P25774 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19567145 | 0.87 | CTSL (0.55) | AKT1CTSLCTSBCTSSALDH1A1 | |
| SCHEMBL17384424 | 0.85 | CTSL (0.50) | AKT1CTSLCTSBCTSSALDH1A1 | |
| SCHEMBL19567152 | 0.84 | CTSL (0.49) | AKT1CTSLCTSBCTSSALDH1A1 | |
| SCHEMBL782348 | 0.84 | AKT1 (0.55) | AKT1CTSLCTSBCTSSMEN1 | |
| SCHEMBL19567156 | 0.83 | CTSL (0.48) | AKT1CTSLCTSBCTSSALDH1A1 | |
| SCHEMBL17384635 | 0.83 | CTSL (0.48) | AKT1CTSLCTSBCTSSALDH1A1 | |
| SCHEMBL19567146 | 0.83 | ALDH1A1 (0.53) | AKT1CTSLCTSBCTSSALDH1A1 | |
| SCHEMBL19193386 | 0.81 | CTSL (0.46) | AKT1CTSLCTSBCTSSALDH1A1 | |
| SCHEMBL1742305 | 0.80 | AKT1 (0.39) | AKT1ALDH1A1HDAC1HDAC2L3MBTL1 | |
| SCHEMBL20187483 | 0.80 | CTSL (0.46) | AKT1CTSLCTSBCTSSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814369-B2 | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-11-14 | — | — | US | disclosed |
| CN-110035996-B | Novel highly relaxant gadolinium chelates for magnetic resonance imaging | 拜耳医药股份公司 | 2022-08-09 | — | — | CN | disclosed |
| US-20210221798-A1 | HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-07-22 | — | — | US | disclosed |
| US-10975060-B2 | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-04-13 | — | — | US | disclosed |
| US-20200283420-A1 | HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-09-10 | — | — | US | disclosed |
| EP-3544964-B1 | HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | Bayer Pharma AG (DE) | 2020-06-17 | — | — | EP | disclosed |
| EP-3544964-A1 | HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | Bayer Pharma Aktiengesellschaft (DE) | 2019-10-02 | — | — | EP | disclosed |
| WO-2018096082-A1 | HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283420-A1 | HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | RXFP1, RXFP2, RXFP3 | AKT1 4839/4885CTSL 3661/4885CTSB 1685/4885 |
| US-11814369-B2 | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging | RXFP1, RXFP2, RXFP3 | AKT1 4839/4885CTSL 3661/4885CTSB 1685/4885 |
| US-10975060-B2 | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging | RXFP1, RXFP2, RXFP3 | AKT1 4839/4885CTSL 3661/4885CTSB 1685/4885 |
| US-20210221798-A1 | HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | RXFP1, RXFP2, RXFP3 | AKT1 4839/4885CTSL 3661/4885CTSB 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.